:

–

Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation,

;

:

–

Schwartz SM, Siscovick DS, Malinow MR et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation,

;

:

–

Verhoef P, Kok FJ, Kluijtmans LA et al. The

C ! T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis,

;

:

–

Wilcken DE, Wang XL, Sim AS, M

redie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C

T mutation. Arterioscler Thromb Vasc Biol,

;

:

–

Brattstro¨m L, Zhang Y, Hurtig M et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis,

;

:

–

Faure-Delanef L, Quere I, Chasse JF et al. Methylenetetrahydrofolate reductase thermolabile variant human longevity. Am J Hum Genet,

;

:

–

Matsushita S, Muramatsu T, Arai H, Matsui T, Higuchi S. The frequency of the methylenetetrahydrofolate reductase- gene mutation varies with age in the normal population. Am Hum Genet,

;

:

–

Tonstad S, Refsum H, Ose L, Ueland PM. The C

T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr,

;

:

–

Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C

T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS Group Atherosclerosis,

;

:

–

Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between

- methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol,

;

:

–

Dettli L. The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol Ther,

;

:

–

van der Put NM, Steegers-Theunissen RP, Frosst P et al. Mutated methylenetetrahydrofolate reductase as a risk factor

,

methylenetetrahydrofolate reductase in neural tube defects. Q J Med.,

;

:

–

Abbate R, Sardi I, Pepe G et al. The high prevalence of thermolabile

–

methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost,

;

:

–

van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation,

;

:

–

Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation,

;

:

–

Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest,

;

:

–

Genest J Jr, M

amara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst (e) ine levels in men with premature coronary artery disease. J Am Coll Cardiol,

;

:

–

Brattstro¨m L, Israelsson B, Norrving B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis,

;

:

–

Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst (e) ine and risk of myocardial infarction in US physicians. JAMA,

;

:

–

Rozen R, Jacques P, Bostom A et al. Interaction of a common mutation in methylenetetrahydrofolate reductase (MTHFR) with low folate status in hyperhomocysteinemia. Am J Human Genet,

;

:A